H.C. Wainwright raised the firm’s price target on Corcept Therapeutics to $40 from $38 and keeps a Buy rating on the shares following the Q1 report. The analyst says the company has a “catalyst-rich” 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics Reveals Q1 2024 Financial Results and Update
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics completes enrollment in Phase 4 CATALYST trial
- Is CORT a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today